Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.61 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | ADH1B | P00325 | 1/20 | 0.56 |
| ▸ | ADH1C | P00326 | 1/20 | 0.56 |
| ▸ | ADH1A | P07327 | 1/20 | 0.56 |
| ▸ | ADH7 | P40394 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1654 | 0.97 | MEN1 (0.78) | MEN1KMT2ATDP1MAOAMAPT | |
| SCHEMBL5799878 | 0.97 | MEN1 (0.78) | MEN1KMT2ATDP1MAOAMAPT | |
| Benzene SCHEMBL11697595 | 0.97 | MEN1 (0.78) | MEN1KMT2ATDP1MAOAMAPT | |
| Fluoride SCHEMBL634375 | 0.94 | MEN1 (0.74) | MEN1KMT2ATDP1MAOAMAPT | |
| SCHEMBL21550054 | 0.94 | MEN1 (0.74) | MEN1KMT2ATDP1MAOAMAPT | |
| Ammonia Solution, Strong SCHEMBL2064651 | 0.94 | MEN1 (0.74) | MEN1KMT2ATDP1MAOAMAPT | |
| SCHEMBL3990993 | 0.94 | MEN1 (0.74) | MEN1KMT2ATDP1MAOAMAPT | |
| Hydrochloric Acid SCHEMBL1862144 | 0.94 | MEN1 (0.74) | MEN1KMT2ATDP1MAOAMAPT | |
| Water SCHEMBL11666905 | 0.94 | MEN1 (0.74) | MEN1KMT2ATDP1MAOAMAPT | |
| SCHEMBL30223761 | 0.94 | MEN1 (0.74) | MEN1KMT2ATDP1MAOAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119350290-A | Method for preparing 1, 4-dioxane-2-ketone from ethylene carbonate | 青岛科技大学 | 2025-01-24 | — | — | CN | disclosed |
| EP-2451792-A2 | PROCESS FOR SUBSTITUTED 3-AMINO-5-OXO-4,5-DIHYDRO-[1,2,4]TRIAZINES | OSI Pharmaceuticals, LLC (US) | 2012-05-16 | — | — | EP | disclosed |
| CN-101560171-B | Preparation method of 5- (N, N-dibenzylglycyl) salicylamide | JIANDE ZISHANWAN FINE CHEMICAL CO LTD | 2012-05-09 | — | — | CN | disclosed |
| US-20120108812-A1 | PROCESS FOR SUBSTITUTED 3-AMINO-5-OXO-4,5-DIHYDRO-[1,2,4]TRIAZINES | OSI PHARMACEUTICALS ,INC. | 2012-05-03 | — | — | US | disclosed |
| WO-2011005909-A2 | PROCESS FOR SUBSTITUTED 3-AMINO-5-OXO-4,5-DIHYDRO-[1,2,4]TRIAZINES | OSI PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| CN-101560171-A | Method for preparing 5-(N,N-dibenzylglycyl) salicylamide | JIANDE ZISHANWAN FINE CHEMICAL (CN) | 2009-10-21 | — | — | CN | disclosed |
| EP-1009447-B1 | HYDROXYMETHYL PHOSPHINE COMPOUNDS FOR USE AS DIAGNOSTIC AND THERAPEUTIC PHARMACEUTICALS AND METHOD OF MAKING SAME | UNIV MISSOURI (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20030045727-A1 | Process for preparing optically active secondary alcohols having nitrogenous or oxygenic functional groups | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-03-06 | — | — | US | disclosed |
| EP-1254885-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE SECONDARY ALCOHOLS HAVING NITROGENOUS OR OXYGENIC FUNCTIONAL GROUPS | Asahi Kasei Kabushiki Kaisha (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-1009447-A4 | HYDROXYMETHYL PHOSPHINE COMPOUNDS FOR USE AS DIAGNOSTIC AND THERAPEUTIC PHARMACEUTICALS AND METHOD OF MAKING SAME | UNIV MISSOURI (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1998041242-A1 | HYDROXYMETHYL PHOSPHINE COMPOUNDS FOR USE AS DIAGNOSTIC AND THERAPEUTIC PHARMACEUTICALS AND METHOD OF MAKING SAME | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 1998-09-24 | — | — | WO | disclosed |
| US-5405872-A | Anti-hypertensive tetralins | BURROUGHS WELLCOME CO. (US) | 1995-04-11 | — | — | US | disclosed |
| EP-0549668-A1 | ANTI-HYPERTENSIVE TETRALINS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-07-07 | — | — | EP | disclosed |
| US-5194450-A | Hypotensive agents | BURROUGHS WELLCOME CO. (US) | 1993-03-16 | — | — | US | disclosed |
| US-5102914-A | Racemic mixtures | BURROUGHS WELLCOME CO. (US) | 1992-04-07 | — | — | US | disclosed |
| WO-1992005143-A1 | ANTI-HYPERTENSIVE TETRALINS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-04-02 | — | — | WO | disclosed |
| US-4336400-A | BRONCHODILATOR AGENTS, CARDIOVASCULAR STIMULANTS | STERLING DRUG INC. (US) | 1982-06-22 | — | — | US | disclosed |
| EP-0030030-A1 | Derivatives of 2-aminoethanol, processes for their preparation, pharmaceutical compositions containing such compounds and the use the latter | CIBA-GEIGY AG (CH) | 1981-06-10 | — | — | EP | disclosed |
| US-4138581-A | BRONCHODILATOR AGENTS, ADRENERGIC STIMULANTS | STERLING DRUGS INC. (US) | 1979-02-06 | — | — | US | disclosed |
| US-4101579-A | Phenethanolamine ethers | ALLEN & HANBURYS LIMITED (GB) | 1978-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045727-A1 | Process for preparing optically active secondary alcohols having nitrogenous or oxygenic functional groups | ADH1A, ADH5, ADH1C | CHRM2 110/4885SIGMAR1 42/4885MEN1 3345/4885 |
| US-20120108812-A1 | PROCESS FOR SUBSTITUTED 3-AMINO-5-OXO-4,5-DIHYDRO-[1,2,4]TRIAZINES | ALKBH5, NT5C, CYP4Z1 | CHRM2 2062/4885SIGMAR1 1634/4885MEN1 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.